Wait For Strategic Decisions Weighs Heavily On Mylan
Executive Summary
With no news on the progress of a board-level strategic review on offer, investors reacted negatively to Mylan falling short of consensus sales figures. This took the firm's share price to its lowest level for more than five years.
You may also be interested in...
US Generics Market Continues To Seek Stability
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
US Generics Market Continues To Seek Stability
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Pfizer Deal Will Dramatically Reshape Mylan’s Model
Following the announcement of a merger between Mylan and Pfizer’s Upjohn, the top executive team that will take charge of the combination has set out its vision for the company.